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Summary Blast cells obtained from 104 children with untreated acute lymphoblastic leukaemia were analysed
for the expression of P-glycoprotein (P-170) and glutathione S-transferase (GST-it) using immunohis-
tochemistry. Expression of P-170 was detected in 36 of 104 patients (35%) and increased GST-i was seen in
52 patients (50%). Coexpression of both resistance proteins was observed in 22 leukaemias (21%), whereas no
evidence of the resistance markers was found in 38 cases (37%). In patients with P-170-positive leukaemic
cells, a significantly lower probability of remaining in first continuous complete remission (CCR) was observed
when compared with patients with P-I70-negative tumours (P< 0.05J. However, only a trend for a more
frequent expression of P-170 was found in the leukaemic cells ofpatients who experienced relapses (P = 0.099).
Overexpression of GST-i was correlated with a higher relapse rate (P = 0.001) and a lower probability of
remaining in first CCR (P = 0.01). Expression of P-170 and GST-i was independent of sex, FAB type,
immunological subtype and initial blast cell count. The multivariate analysis indicated that only the expression
of P-170 is an unfavourable prognostic factor for children with acute lymphoblastic leukaemia in addition to
the prognostic clinical factors.
The results of chemotherapy on childhood acute lymphoblas-
tic leukaemia (ALL) have been markedly improved during
the past decade (Riehm et al., 1992). The remission rate of
patients treated with chemotherapy is more than 95%, and
the long-term disease-free survival rate about 75%. In spite
of these excellent results, 25% of the patients will experience
a relapse with a poor prognosis. The search for risk factors
to define patients at high risk of relapse who need a different
or more aggressive therapy is thus a current problem.
Primary resistance to chemotherapeutic agents may be an
important reason for relapses in ALL. During the past few
years, the phenomenon of multidrug resistance (MDR) has
been described, and some of its molecular aspects have been
clarified (Endicott & Ling, 1989). The MDR phenotype is
characterised by cross-resistance to a range of widely used
chemotherapeutic agents (e.g. anthracyclines, vinca alkaloids
and epipodophyllotoxins). Frequently, MDR cells overex-
press a transmembrane 170 kDa protein known as P-glyco-
protein or P-170. P-glycoprotein-mediated drug resistance
results in reduced drug accumulation in tumour cells as a
result of increased efflux. Results obtained in different
tumour types confirm the significance of the expression of
P-170 for the clinical drug resistance (Chan et al., 1990; Volm
et al., 1992a). Some reports also indicate that P-170 expres-
sion may influence the therapeutic outcome in acute
leukaemia (Pirker et al., 1991; Campos et al., 1992; Goasguen
et al., 1993). However, the number of patients included in
ALL studies was small and the prognostic value of P-170 in
childhood ALL has been not unequivocally clarified. Fur-
thermore, not all multidrug-resistant tumours express P-170,
so that refractoriness to chemotherapy can only partly be
explained by the expression of P-170. This suggests that other
mechanisms are also implicated in the acquisition of resis-
tance. For instance, glutathione S-transferases are isoenzymes
which conjugate glutathione with various xenobiotics (Black
& Wolf, 1991). These proteins may therefore play an impor-
tant role in the detoxification of drugs (e.g. cyclophos-
phamide and anthracyclines) which are involved in ALL
therapy.
Therefore, the aim of the present investigation was to
assess the prognostic value of P-glycoprotein and glutathione
S-transferase x in a retrospective study of 104 children with




Blast cells from bone marrow or peripheral blood from 111
children (52 boys and 59 girls) with newly diagnosed non-B-
type acute lymphoblastic leukaemia (ALL) were collected
and cryopreserved. However, seven patients died within 30
days after starting therapy as a result ofcomplications (infec-
tion, bleeding) and were dismissed from the evaluation. The
criterion for patient selection was the availability of cell
probes. All patients with available cells were enrolled in this
retrospective study.
The diagnosis of leukaemia was made by standard
cytological and histochemical examination of bone marrow
and blood smears according to the French-American-
British (FAB) Classification (Bennett et al., 1976) and by
immunological investigation of the blast cells using indirect
immunofluorescence. Patients were divided into three sub-
groups: (1) precursor B-ALL (HLA-DR, CD19), (2) common
(c)-ALL (HLA-DR, CD1O, CD19) and (3) T-ALL (CD1,
CD2, CD7). The CD13, CD33 and CD65 antigens were
examined in order to define myeloid markers. Complete
remission was diagnosed if the blast cell content was less
than 5% in an otherwise normocellular marrow on day 33
after the onset of the therapy without evidence of blast cells
at extramedullary sites. Patients were diagnosed to have
isolated bone marrow relapses if they had >25% blast cells
in the marrow with no evidence of leukaemia at extramedul-
lary sites. Marrow involvement was diagnosed in patients
with proven leukaemia at extramedullary sites and at least
5% detectable bone marrow blasts. Isolated relapses were
those with clinically overt manifestation of leukaemia at
extramedullary sites (e.g. lymphoblasts in the cerebrospinal
fluid or histologically confirmed testicular infiltration) and
less than 5% blasts in the bone marrow. In this study, the
term relapse means recurrent disease at any site and at any
time.
Therapy
All 104 patients received therapy according to cooperative
modified BFM protocols. [ALL-VII/81, ALL-VIII/87 (Zintl
et al., 1993) and ALL-BFM-90 (Riehm et al., 1992)]. These
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treatment protocols consist of induction therapy with pred-
nisone, vincristine, daunorubicin and L-asparaginase followed
by consolidation therapy with cyclophosphamide, cytarabine,
6-mercaptopurine and intrathecal methotrexate (MTX).
Patients included in study ALL-VII/81 (66 patients) and
ALL-VIII/87 (22 patients) received intermediate-dose intra-
venously MTX (0.5 or 1 gm-2); patients included in study
ALL-BFM-90 (16 patients) received high-dose MTX (5 g
mr-2). Maintenance therapy was performed with oral 6-
mercaptopurine (daily) and methotrexate (weekly) for up to 2
years after starting therapy. The different therapeutical proce-
dures had no significant effects on the probability of remain-
ing in continuous complete remission of the patients included
in our study (P= 0.11).
Leukaemic cells
Cell samples were collected in heparinised flasks and mono-
nuclear cells were isolated by Ficoll-Hypaque density
gradient centrifugation. After washing twice in culture
medium (RPMI-1640) the cells were cryopreserved in liquid
nitrogen with 10% dimethylsulphoxide and 5% fetal calf
serum using a programmed freezer. All cell samples con-
tained at least 80% blast cells, examined by May-Griiwald-
Giemsa staining.
Immunohistochemical methods
For measuring P-glycoprotein (P-170) and glutathione S-
transferase i (GST-r) cell samples were resuspended in
Hanks' balanced salt solution (Biochrom, Berlin, Germany)
and the viability of cells was tested by staining with
methylene blue. Cell suspensions were centrifuged with a
Cytospin II (Shandon, Frankfurt, Germany), resulting in a
cell monolayer. After air drying the cells were fixed in
ice-cold acetone for 10min and stored at -20°C. Immuno-
histochemical investigations were performed using the strep-
tavidin-biotin peroxidase complex method (Volm et al.,
1988). Cell preparations were briefly preincubated with hyd-
rogen peroxide (0.3%; 15 min), unlabelled streptavidin (dilu-
tion 1:50, 15 min) and non-immune normal serum. For the
detection of P-170 we used the murine monoclonal antibody
C 219 (Isotopendiagnostik, Dreieich, Germany) with spec-
ificity to an internal epitope of P-170 as the primary
antibody. The final antibody concentration was 10 gsg ml-'.
A rabbit polyclonal antibody (GST-n, dilution 1:2,000;
kindly provided by Dr K. Satoh, University School of
Medicine, Hirosaki, Japan) was used for the detection of
GST-7t. The primary antibodies were applied for 16 h at 4°C
in a moist chamber. After three washes in phosphate-buffered
saline (PBS) the cells were incubated for 30 min with
biotinylated sheep anti-mouse IgG (Amersham, Braun-
schweig, Germany) for the detection of P-170 and with goat
anti-rabbit IgG (Dianova, Hamburg, Germany) for the detec-
tion of GST-r (both diluted 1:50 with 5% normal human
serum). Afterwards, the streptavidin-biotinylated peroxidase
complex (Amersham; 1:100, 30 min) was added. Peroxidase
activity was made visible with 3-amino-9-ethylcarbazole
(15 min), which gives a red-brown reacting product.
Counterstaining was performed with haematoxylin and the
sections were mounted with glycerol gelatine. Negative con-
trols were obtained firstly, omitting the primary antibodies
and secondly by repeating all steps except for substitution the
primary antibody by an irrelevant antibody. Positive controls
for P-170 were performed using 40-fold doxorubicin-resistant
L1210 mouse leukaemic cells which have a high expression of
P-170, and as positive controls for GST-ir detection we used
the 300-fold doxorubicin-resistant murine sarcoma cell line
S180/DOX (Volm et al., 1988; Efferth et al., 1992).
Three observers (M.V., H.G. & A.S.) independently
evaluated and interpreted the results of immunohistochemical
staining without knowing the clinical data. The evaluations
were in agreement in 90% of the samples. The remaining
patients were re-evaluated. Five hundred cells were counted
in each sample. Patients were considered to positive for
P-l70-expression if at least 1% of the leukaemic cells were
positively stained.
Because positive immunostaining was found not only in
malignant cell populations but also in macrophages (Schlaifer
et al., 1990) we distinguished between tumour cells and
macrophages using MAb CD68 (Dako-CD 68, Kpl, Dako-
pats, Copenhagen, Denmark). In addition, the cells were
judged by staining with haematoxylin for morphological
criteria of leukaemic cells. Staining for GST-c was classified
only on the basis of intensity (0= negative, 1 = weak,
2 = moderate, 3 = high). Since GST-n was expressed at a
baseline level in all cells, values of 0 and 1 were considered to
negative, values of 2 and 3 positive.
Statistical analyses
We used Fisher's exact test to examine whether there is a
correlation between clinical data, resistance markers and
relapse rates. Life table analyses according to Kaplan and
Meier (1956) were performed for relapse-free intervals; the
groups were compared by log-rank tests.
The prognostic influence of clinical and molecular
parameters was assessed by multivariate regression methods
(Cox model; Cox, 1972) as described by Byar (1982).
Results
In the present study 104 patients with untreated non-B-type
acute lymphoblastic leukaemic were analysed using immuno-
histochemistry for the expression of P-glycoprotein (P-170)
and glutathione S-transferase x (GST-n) in relationship to
their therapy outcome. The patients' data are given in Table
I. The prognosis of the patients is largely determined by the
initial peripheral blast cell count (PBC). Patients with PBC of
50,000 mm-3 or more tended to have more relapses (P =
0.08, Table I). The probability of remaining in first con-
tinuous complete remission (CCR) was significantly lower
(P = 0.029). In this retrospective study we found no correla-
tion between age, sex and immunological subtype on the one
hand and relapse rate and relapse-free intervals on the other
hand. The median follow-up of this group was 8 years (range
0-12 years).
P-170 expression was found in 36 out of 104 leukaemias
(35%), while 68 patients (65%) failed to express P-170 in the
leukaemic cells (Table II). The proportion of positively
stained cells ranged from 1 to 100%. The intensity of stain-
ing also varied. Figure la shows a typical immunohis-
tochemical staining of P-170. In our study 38 out of 104
patients (37%) experienced relapses. In the population who
experienced relapses, 17 patients (45%) were P-170 positive.
In the group without relapses (66 patients) P-170-positive
cells were seen in only 19 patients (29%) (P = 0.099; Table
II). A life table analysis for the relapse-free interval of P-170-
positive and P-170-negative patients (n = 104) is shown in
Figure 2. Patients with P-170-positive blast cells had a
significantly lower probability of first CCR (P = 0.03).
Overexpression of GST-it was present in 52 of the 104
cases (50%). The staining was homogeneous in the cytoplasm
(Figure lb) and a high percentage of cells (80-100%) had
the same intensity of staining in each sample. GST-t overex-
pression was detectable in 27 out of 38 patients who
experienced relapses (71%). In contrast, in the group without
relapses only 25 out of 66 patients (38%) were GST-i
positive. The relapse rate was significantly higher in
leukaemias with an overexpression of GST-i (P = 0.001,
Table II). The probability of first CCR in the GST-n-positive
patients were significantly lower (P = 0.01, Figure 3).
Coexpression of P-170 and GST-i was observed in 22
leukaemias (21%). The blast cells of 14 patients (13%) were
P-170 positive but GST-i negative. In 30 leukaemias (29%)
only a GST-i overexpression was found. In 38 leukaemias
(37%) neither P-170 nor GST-it expression was detected. To
determine whether the combination of P-170 and GST-n has
a higher prognostic significance, the patients were grouped1146 A. SAUERBREY et al.
Table I Patient data
Patients Relapses P-value RFI° P-value
(relapses) (Fisher's exact test) (log-rank test)
Age (years)
< 1 3 (0)
1-9 77 (29)
10 24 (9) NS NS
Sex
Male 46 (18)
Female 58 (20) NS NS
FAB type
LI 76 (26)
L2 28 (12) NS NS
Immunological subtypeb
Precursor B-ALL 17 (7)
c-ALL 47 (16)
T-ALL 33 (15) NS NS
PBc m-3
<50,000 61 (18)
> 50,000 43 (20) 0.08 0.029
'RFI, relapse-free interval. bSeven patients were not available for immuno-
phenotyping. CPBC, peripheral blast cell count. NS, not significant (P-value >0.1).
Table II Relationship between relapse rate and P-170 or GST-it
expression
Patients No relapse Relapse
n n (%) n (%) P-value
P-170 negative 68 47 (69) 21 (31) 0099
P-170 positive 36 19 (53) 17 (47)
GST-ir negative 52 41 (79) 11 (21) 0.001









of P-170-positive a and GST-x-
on the basis of the expression of P-170 and GST-i. Figure 4
shows that the prognosis of the patients according to the
probability of remaining in first CCR is more unfavourable
by combining both proteins. Similar results were obtained for
the relapse rate (Table III). Thirteen out of 22 patients (59%)
in the group with coexpression of P-170 and GST-i relapsed.
In contrast, only seven of the 38 patients (18%) with no
evidence of either resistance protein experienced relapses.
Among the 14 patients whose blast cells were P-170 positive
but GST-ic-negative, four (29%) experienced relapses; among
the 30 patients with GST-ir-positive and P-170-negative blast
cells 14 (47%) developed relapses.
We further analysed the prognostic impact of P-170 and
GST-i on the time to relapse in the presence of clinical
prognostic factors by multivariate regression methods (Cox
regression model). The full model including age, sex, FAB
type, immunological subtype, initial peripheral cell count
Years
Figure 2 Kaplan-Meier curves of the relapse-free interval in
children with P-170-positive vs P-170-negative ALL.
(PBC) as well as P-170 and GST-ir revealed a highly
significant influence of PBC (P=0.001) and a borderline
significant influence of P-170 (P=0.08), whereas all other
factors including GST-i were of no significant influence
(P>0.10). An analysis of the reduced model with only PBC
and P-170 as covariates resulted in a significant influence of
both PBC (P = 0.0001) and P-170 (P = 0.025). The indepen-
dent effect of P-170 on disease-free survival (in addition to
PBC) could be confirmed by an analysis of deviance
(deviance= - 2 [log likelihood (PBC) - log likelihood (PBC,
P-170)] = -2 [(- 164.17) - (- 161.91)] = 4.52, P<0.05).
P-170 and GST-c were not totally independent of each
other (value of the chi-square test for independency = 2.72,
P = 0.10). Therefore we checked for a possible prognostic
influence of GST-ir in addition to that of PBC and P-170 as
well as when replacing P-170 by GST-nc. Both analyses
resulted in no significant additional influence of GST-ic
(P = >0.05).
Discussion
Expression of the multidrug resistance gene (MDR-J) or its
gene product (P-170) has been found in many human solid
Figure 1 Typical staining
positive b, ALL cells.RESISTANCE PROTEINS IN ALL 1147




P-170 negative/GST-ir negative 38 7 (18)
P-170 positive/GST-n negative 14 4 (29)
P-170 negative/GST-n positive 30 14 (47)
P-170 positive/GST-ir positive 22 13 (59)
Years
Figure 3 Kaplan-Meier curves of the relapse-free interval in
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Figure 4 Kaplan-Meier curves of the relapse-free interval in
children with (1) P-170-negative/GST-n-negative (n = 38), (2) P-
170-positive/GST-ir-negative (n = 14), (3) P-170-negative/GST-n-
positive (n = 30) and (4) P-170-positive/GST-n-positive ALL
(n = 22).
tumours (Chan et al., 1990; Efferth et al., 1992; Volm et al.,
1992b) and in leukaemias (Pirker et al., 1991; Campos et al.,
1992). Most studies of leukaemias were performed with acute
non-lymphoblastic leukaemia (ANLL) (Holmes et al., 1989;
Sato et al., 1990), whereas only few reports on acute lym-
phoblastic leukaemia (ALL) exist (Rothenberg et al., 1989;
Pieters et al., 1992; Goasguen et al., 1993). Using immunohis-
tochemical methods (Musto et al., 1990) or immunoblot
techniques (Kuwazuru et al., 1990) P-170 expression was
found in six out of 12 and in four out of 11 adult ALL
patients respectively. In addition, increased MDR-J mRNA
transcripts were found in five of 14 adults with ALL (Gruber
et al., 1992). In a recent work Goasguen et al. (1993) found
P-170 expression in 12 out of 36 children (33%) with newly
diagnosed ALL. In contrast to these results, Rothenberg et
al. (1989) found an expression of P-170 in only one out of
nine adult ALL patients. Using the monoclonal antibody
MRK-16 no expression of P-170 was found in 13 ALL cases
(Ito et al., 1989). Pieters et al. (1992) analysed cells from 28
untreated ALL patients and found that all samples were
P-170 negative. In addition, Ubezio et al. (1989) found no
increased MDR-J mRNA levels in resistant childhood ALL.
These conflicting data were the reason why we decided to
determine P-170 in a retrospective study with 104 children
with newly diagnosed ALL. In our study we found expres-
sion of P-170 in 36 out of 104 samples (35%). One reason for
the different results may be the use of different immunohis-
tochemical evaluation criteria. In agreement with other inves-
tigators (Musto et al., 1990; Goasguen et al., 1993) the
patients in our study were considered to be positive for P-170
if at least 1% of the leukaemic cells were stained. In our
opinion, residual disease can also be established by such
small cell proportions. For this reason we used this cut-off
point for positivity.
We found similar significant results using a cut-offpoint of
5% or 10% P-170-positive cells (data not shown).
We also compared the results of P-170 with the clinical
outcome. As response criteria we used the relapse rate and
the relapse-free interval. Both parameters reflect the respon-
siveness to the applied therapy. We found a significantly
lower probability of remaining in first continuous complete
remission (CCR) (P = 0.033) and a tendency for an increased
relapse rate in patients with P-170-positive blast cells
(P = 0.099). Similar results were published on adult ALL on
the basis of MDR-J mRNA detection (Marie et al., 1991;
Gruber et al., 1992). Musto et al. (1991) reported a high risk
of early relapse in leukaemia patients with detectable P-170-
positive cells in complete remission. Our results may be
explained by a selective survival of P-170 cells during the
primary therapy. These surviving cells may lead to a minimal
residual disease with an increased risk of recurrent disease.
The data indicate that the expression of P-170 is a prognostic
factor for both relapse rate and relapse-free interval of
patients with ALL in addition to clinical prognostic factors.
Several studies suggest that refractoriness to chemotherapy
is only partly caused by P-170 and that other resistance
mechanisms are also involved in this process (Moscow et al.,
1989; Tiedefelt et al., 1992; Volm et al., 1992a). Therefore, we
also analysed the expression of GST-i in the same patients.
We found increased GST-c levels in the blast cells from 52 of
104 patients (50%). Because of its physiological function
GST-i expression was found in all samples at a low level so
that only patients with moderate or intensive staining were
considered to be positive for GST-7c overexpression. Gekeler
et al. (1992) reported moderate GST levels in patients with
the initial stage of ALL and with relapsed ALL at the
mRNA levels when compared with the cell line CCRF-CEM.
Results obtained on initial stage of non-Hodgkin's lym-
phoma (NHL) (Rodriguez et al., 1993) and relapsed stage of
NHL (Cheng et al., 1993) also suggest an involvement of
increased GST-ic levels in drug resistance of lymphatic
tumours. Increased levels of GST-ir mRNA have also been
observed in untreated adult leukaemias (McQuaid et al.,
1989). Tidefelt et al. (1992) found that 23 of 59 patients with
ANLL were positive for GST-I overexpression using the
same discriminating criteria for GST-i estimation as in our
study. In addition, in 95% of patients with chronic lym-
phocytic leukaemia (CLL), Schisselbauer et al. (1990) found
detectable GST-i levels and a quantitatively increased GST
activity in chlorambucil-resistant CLL patients. To our
knowledge the present study is the first investigation into the
prognostic importance of GST-r in childhood ALL. Our
data show an association between increased GST-it levels and
a higher relapse rate (P = 0.003) as well as a lower pro-
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Furthermore, our study suggests a tendency for simul-
taneous expression of P-170 and GST-i (P = 0.099) and the
two parameters are probably not independent of each other.
Similar results were obtained in NHL (Cheng et al., 1993)
and in lung tumours (Volm et al., 1991, 1992a). In contrast
to this, no correlation was found between the parameters in
primary NHL (Rodriguez et al., 1993). Holmes et al. (1990)
observed GST-i overexpression independent of MDR-J gene
expression. By combing both parameters in our study, the
prognostic significance with respect to the relapse-free inter-
val and the relapse rate was improved. In a univariate
analysis we showed that P-170- and GST-c overexpression
were independent of sex, FAB type, immunological subtype
and the peripheral blast cell count. Goasguen et al. (1993)
observed a significantly higher expression of P-170 in B-type
ALL vs precursor B-ALL. We investigated six patients with
B-ALL and found four to be positive for P-170 (unpublished
data). In fact, the staining in these cells was more intensive
and the proportion of positive cells was higher than in non-
B-ALL. B-ALL indeed is known to have different biological
and clinical features when compared with non-B-ALL, and
so these patients are treated differently. This was the reason
why we excluded B-ALL patients from our study.
Although we observed a significant prognostic power of
GST-c in the univariate analysis (P = 0.032), this could not
be confirmed in the multivariate analysis when PBC and
P-170 were included. The effect of GST-ic seems partly to be
due to its minor correlation (P = 0.10) with P-170 and pos-
sibly higher order effects which have been beyond the aim of
this investigation. Thus, our results suggest that only P-
glycoprotein has prognostic significance in ALL. In earlier
investigations we found that no correlation exists between the
expression of dihydrofolate reductase, thymidylate synthase,
DNA topoisomerase II or metallothionein and the clinical
outcome of children with ALL (Sauerbrey et al., 1994; Stam-
mler et al., 1994; Volm et al., 1994a).
Since drug resistance remains the major obstacle in the
treatment of the lymphoblastic leukaemia, interest has also
focused on the elucidation of molecular mechanisms of
resistance. Although our knowledge as to which factors are
responsible for a regulated coexpression of resistance
mechanisms is limited, one possibility is that the resistance
factors belong to a set ofgenes which is controlled by general
regulatory mechanisms. Indeed, the c-fos/c-jun protein com-
plex which binds specifically to AP-1 affects the transcrip-
tional expression of several cellular genes. Interestingly,
P-glycoprotein and glutathione S-transferase contain an AP-1
motif, thus these genes may also be regulated by the cellular
oncogenes c-fos and c-jun (Angel & Karin, 1991; Teeter et al.,
1991). Indeed, in earlier studies (Volm et al., 1994b) we found
that the relapse-free intervals were lower in patients with
Fos- and Jun-positive leukaemic cells than in patients with
Fos- and Jun-negative tumour cells. Additionally, nuclear
protein kinase C is of high functional importance as a
stimulator of the activity of proto-oncogenes such as c-fos
and c-jun. Earlier results of univariate and multivariate
analyses demonstrated that in addition to the clinical prog-
nostic indicators protein kinase C is a significant prognostic
factor for relapse rate, relapse-free intervals and overall sur-
vival times in ALL of children (Volm et al., 1994c).
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